• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

HCV launch

Quote
Anonymous said:
anemia dependent upon what the baseline Hb levels were. Start with higher levels in clinical trials (13-M, 12-F) than what is seen in real-world population and have 2gm/dL drop and won't have it drop below what is considered anemia in HCV trial (less than 10). We'll see what happens when patients with baseline lower than 13 or 12 start on a RBV containing regimen
Click to expand...

Patients with decompensated cirrhosis may have low baseline Hgb but the large majority of HCV patients have normal Hgb levels like you and me. The baseline Hgb levels in the Ion trials were 12-14 also. There's no evidence to suggest HCV patients are all walking around with anemia. More Gilead hype.
 




Anonymous said:
Patients with decompensated cirrhosis may have low baseline Hgb but the large majority of HCV patients have normal Hgb levels like you and me. The baseline Hgb levels in the Ion trials were 12-14 also. There's no evidence to suggest HCV patients are all walking around with anemia. More Gilead hype.
Click to expand...

You are obviously a abbvie inexperienced hcv person. Many patients have a low hgb. But the studies are designed for patients to finish the trial. You are wrong
 








Anonymous said:
You are obviously a abbvie inexperienced hcv person. Many patients have a low hgb. But the studies are designed for patients to finish the trial. You are wrong
Click to expand...

No, HCV does not cause anemia unless the patient is cirrhotic. As you should know, only 20% of patients with HCV develop cirrhosis and 4% of the cirrhotics develop HCC. So, the large majority of HCV patients are not anemic. Also, as you should know, we only had a 1% discontinuation rate due to AEs in over 2,700 patients studied. Even if someone does develop anemia, it can be treated through with a RBV dose reduction. Again, more Gilead hype.
 




Anonymous said:
No, HCV does not cause anemia unless the patient is cirrhotic. As you should know, only 20% of patients with HCV develop cirrhosis and 4% of the cirrhotics develop HCC. So, the large majority of HCV patients are not anemic. Also, as you should know, we only had a 1% discontinuation rate due to AEs in over 2,700 patients studied. Even if someone does develop anemia, it can be treated through with a RBV dose reduction. Again, more Gilead hype.
Click to expand...

Oh well I thought the cirrohtic patients were our clinical adv. ???
You are still naive and your 19 years here shows
 
























Are doctors warehousing Harvoni and Sovaldi scripts in lieu of the pending Viekirax approval? No! Rxs for Harvoni have been accelerating weekly since launch! I bet you can't wait to get approval and kick Gilead's butt! :(
 




Read in Seeking Alpha that Harvoni Rxs were up 46% last week! The rest of this month is vacation time for most of us so who care if we get approval this week or next week. If we get a deficiency letter from FDA, launch will be Summer 2015 and most patients will be cured with Harvoni. Merry Christmas!
 




Anonymous said:
Read in Seeking Alpha that Harvoni Rxs were up 46% last week! The rest of this month is vacation time for most of us so who care if we get approval this week or next week. If we get a deficiency letter from FDA, launch will be Summer 2015 and most patients will be cured with Harvoni. Merry Christmas!
Click to expand...

Quit the negativity! We will be fine with a 5% market share. There is nothing close in the pipeline. Take the money and RELAX!
 
































Top Bottom
Back
Quote